Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program

CAR-T Digest - August 2020

Weekly Digest - March 2026

25 March 2026: Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program

Tempus has entered into a strategic collaboration with Daiichi Sankyo to support the development and differentiation of an ADC program using AI-driven approaches in oncology
The partnership aims to address a key challenge in ADC development identifying the right patients and biomarkers by integrating clinical trial data with large-scale real-world datasets
The collaboration leverages Tempus multimodal AI platform, including PRISM2, to integrate pathology images and clinical data and generate insights for biomarker discovery and patient stratification
Through this approach, the companies will develop proof-of-concept AI models to improve patient selection, generate response maps, and enable more precise clinical trial design, including better benchmarking of control arms
Overall, this collaboration highlights the growing role of AI in enhancing clinical development of ADCs, with the potential to improve trial efficiency, optimize outcomes, and better match therapies to patients